ARTICLE | Company News
Amicus to build U.S. biologics facility
February 2, 2018 8:21 PM UTC
Amicus Therapeutics Inc. (NASDAQ:FOLD) plans to spend up to $200 million to build a new biologics facility in the U.S. for its Pompe's disease program, CEO and Chairman John Crowley told BioCentury. The company said various locations outside the U.S. had been under consideration...
BCIQ Company Profiles
BCIQ Target Profiles